Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Bioavailability
Interventions: Fentanyl Sublingual Spray (FSS), Fentanyl Citrate Injection (FCI), Naltrexone; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes, Hypertriglyceridemia
Interventions: Saxagliptin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Acute Bleeding on Long-Term Anticoagulation Therapy, Hemorrhage, Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time), Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation
Interventions: 4-factor prothrombin complex concentrate (4FPCC); Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 125 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy Volunteers
Interventions: Febuxostat XR, Maalox Advance Regular Strength liquid; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza
Interventions: Community-based vaccine outreach intervention; Biological
Lead sponsor: The New York Academy of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: 50 mg Usnoflast, 75 mg Usnoflast, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: La Jolla, California • Orange, California • San Francisco, California + 12 more

Conditions: Congestive Heart Failure, Congestive Heart Failure(CHF), Congestive Heart Failure (CHF), Congestive Heart Failure Chronic
Interventions: ADAPT; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Heart Arrest
Interventions: Preemptive Rapid Response Team intervention; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Menstrual Irregularity
Interventions: Artificially Sweetened Carbohydrate Beverage, Artificially Sweetened Beverage; Dietary Supplement
Lead sponsor: University of Colorado, Colorado Springs; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Dystonia, Drug Induced Dystonia, Parkinson Disease, Essential Tremor, Dyskinesias, Myoclonus, Tic Disorders, Torticollis, Ulnar Nerve Entrapment, Temporomandibular Joint Disorders, Dysphonia
Interventions: DystoniaNet-based diagnosis of isolated dystonia; Diagnostic Test
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Abdominal Aortic Aneurysm (AAA)
Interventions: Assess AAA rupture risk by PET-CTA scans, 18F-fludeoxyglucose (FDG), 11C-PBR28; Drug · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 45 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Postural Tachycardia Syndrome
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy
Interventions: FDG, Ketone Drink, Ketogenetic Diet; Drug · Dietary Supplement · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uncomplicated Urinary Tract Infection, Cystitis
Interventions: Omadacycline tablets, Nitrofurantoin capsules; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 23
States / cities: Chula Vista, California • La Mesa, California • Los Angeles, California + 17 more

Conditions: SCI - Spinal Cord Injury
Interventions: Intermittent theta burst stimulation (iTBS), Functional electrical stimulation (FES), Transcutaneous spinal cord stimulation (TSCS), Sham Intermittent theta burst stimulation (iTBS); Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Status Epilepticus, Coma
Interventions: Rapid Response EEG; Device
Lead sponsor: Children's Hospital at Montefiore; Other
Eligibility: 2 Years to 18 Years
Enrollment: 60 participants
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cardiac Conduction and Repolarization
Interventions: Custirsen, Placebo, Moxifloxacin; Drug
Lead sponsor: Achieve Life Sciences; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Traumatic Brain Injury (TBI)
Interventions: Vigorous exercise, Light to moderate exercise; Other
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 79 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Cetirizine Hydrochloride 10 mg tablets, single dose, Zyrtec® 10 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Osteoarthritis, Knee, Pain
Interventions: Test Article; Drug
Lead sponsor: Pure Green; Industry
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: West Bloomfield, Michigan

Conditions: Diabetes, Gestational Diabetes, Diabetes Mellitus, Type 2
Interventions: 2 hour glucose tolerance test using 75g glucose drink; Diagnostic Test
Lead sponsor: Pediatrix; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Fibromyalgia
Interventions: Paced Auditory Serial Addition task (PASAT); Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diseases/Diagnoses, Genetic Disease
Interventions: Rapid whole genome sequencing (StatSeq); Other
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Up to 4 Months
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Hermanski-Pudlak Syndrome, Colitis, Cytokines, Lymphocytes, Drug Evaluation
Interventions: Mesalamine, Infliximab, Corticosteroids, 6-Mercaptopurine, Tacrolimus, Adalimumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions

Effects of DPP-4 Inhibition on Triglycerides

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

Rapid Vaccination of Hard-To-Reach Populations

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Palliative Care for People With HF

Patient Acuity Rating: a Tool to Prevent In-Hospital Cardiac Arrest

Timing of Energy Availability on Menstrual Cycle Function

Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia

Predictors of AAA Expansion and/or Rupture

Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.

Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging

Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis

A Novel Repetitive Synchronized Associative Stimulation Neuromodulation Approach for Spinal Cord Injury Patients

Rapid-Response EEG in Children With Suspected Status Epilepticus

Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization

Effect of Exercise Training on Physical, Cognitive, and Behavioral Function in People With TBI

A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions

Osteoarthritis of the Knee Pain Study Using a CBD and THC Sublingual Tablet

GDM Post Partum Screening

Generalized Hypersensitivity in Patients With Fibromyalgia Syndrome

Genomic Sequencing in Acutely Ill Neonates

Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome